Summary In order to examine in detail the sensitivity to chemotherapy of tumour cells at various organ sites and at various stages of metastasis, we have used a series of cell lines, all selected from sister subpopulations derived from a single mouse mammary tumour, which can be distinguished and quantitated from normal cells and from each other through growth in selective medium. For the studies described here, we used two lines, 4T07 and 66FAR, which will form colonies in vitro in medium containing 60 iM 6-thioguanine 
For metastases to occur in a secondary organ site, a series of sequential events must occur (Fidler, 1978) . Agents which inhibit metastasis are usually evaluated by determining their effect on the final outcome of this metastatic sequence, either by the overall effect on survival or by comparing the number or size of metastatic nodules which develop in treated vs control animals. By using a series of mouse mammary tumour cell lines with selectable markers, we have been able to follow the development of experimental lung and liver metastases from cell injection through the appearance of visible nodules (Aslakson et al., 1991a) , and have described immunological treatments which inhibit lung colonisation at two different steps in the metastatic sequence (Aslakson et al., 1991b) . These tumour cell lines were selected from sister subpopulations derived from a single mouse mammary tumour. Both the parent subpopulations and several of the lines with selectable markers have been extensively characterised, and have been shown to differ in many characteristics, including sensitivity to several chemotherapeutic drugs Miller et al., 1989a; Miller et al., 1989b; Miller et al., 1991) , ability to metastasise from a subcutaneous site (Miller et al., 1983) , and ability to form experimental metastases in lung and liver (Aslakson et al., 1991a) . We have chosen to use this model system to examine the sensitivity to chemotherapy of these tumour cells at various steps in the metastatic sequence and in subcutaneous tumours. We report here a comparison of two cell lines in response to melphalan. Interpretation of studies involving drug exposure in vivo may be complicated by drug pharmacokinetics, in that it is difficult to be certain of the exact concentrations and timing of tumour cell exposure to drug. We have chosen to use the drug melphalan because it is very short-lived under physiological conditions (Parsons et al., 1981) , so the time of tumour cell exposure to drug is limited. In addition, melphalan does not require metabolic activation, and the relationship between its in vitro and in vivo cytoxicity has been shown to be relatively straightforward (Frei et al., 1988 
Material and methods

Mice
Male BALB/c mice 8 to 12 weeks old were produced in our animal colony, which was established by caesarean derivation of a litter of mice from BALB/cfC3H parents obtained from the Cancer Research Laboratory, Berkeley, CA. Tumour cell lines used in the experiments described here grow and respond to chemotherapy equally well in male and female mice.
Tumour cell lines Tumour subpopulation lines 66 and 410.4 were isolated from a single spontaneously arising mammary tumour from a BALB/cfC3H mouse (Miller et al., 1983; Dexter et al., 1978) . Line 66FAR is a diaminopurine (and fluoradenine) -resistant variant of line 66 obtained by stepwise selection in increasing concentrations of diaminopurine, followed by 5-fluoroadenine. Line 4T07 is a thioguanine-, ouabain-resistant variant of line 410.4 (Miller et al., 1987) . Doubling times for these cultures in vitro were approximately 15 h, 18 h, and 13 h for lines 4T07, 66FAR, and 66, respectively (n = 3). Plating efficiencies averaged 64% (n = 8 cultures per cell line) and were not significantly different for the three lines.
Subcutaneous tumours Cells from culture were suspended as above, at 3 x 106 cells ml-'. Cells were injected s.c. on the right flank, at 0.1 ml/mouse. Tumour size was measured in two perpendicular diameters with Vernier calipers twice a week.
Melphalan treatment Melphalan (Sigma Chemical Co., St. Louis, MO) was prepared immediately before use by suspending in acid alcohol (1 ml of 12 N HCI in 120 ml 95% ethanol) to 40 mg ml-,, diluting in acid saline (0.05 N HCI in 0.15 N NaCl) to 18 mg ml', then diluting with 0.5% (w/v) carboxymethylcellulose (Sigma Chemical Co.) in phosphate-buffered saline to a final concentration of 1.8 mg ml-' (Schmid, et al., 1980) . Melphalan solutions were prepared so as to insure a minimum time lapse between dissolving the melphalan powder and injecting the mice, because the solutions are unstable. We performed a bioassay to determine the stability of these injectable solutions by treating monolayer cultures with melphalan solution stored at room temperature for various times; loss of activity was not significant for up to 1 h storage, but subsequently, the loss of activity accelerated rapidly. Consequently, we always were careful to prepare and use melphalan solutions as soon as possible (always within 1 h) after dissolving the melphalan powder. Mice were weighed and injected with up to 18 mg kg-' melphalan i.p.
(0.01 ml per g body weight). This dose was non-lethal for up to 48 h. Only five mice receiving this dose were retained for longer times; one in five died at day 18 after treatment but the cause of death may have been metastatic disease rather than drug toxicity. Untreated control mice received 0.3 ml vehicle (acid alcohol, acid saline, carboxymethylcellulose in phosphate-buffered saline mixture without melphalan). The melphalan solution of 1.8 mg ml-' was diluted with vehicle in order to inject lower doses for dose-response curves.
Recovery of colony-forming cells At various times after injection of cultured tumour cells, groups of mice were killed by cervical dislocation. Lungs were removed aseptically, weighed, placed in Hanks buffer, and minced finely. Lungs were dispersed by a combination of physical and enzymatic techniques, as previously described (Miller et al., 1990) . Briefly, minced lungs were presoaked for 1 h at 0°C in 5 ml of enzyme solution consisting of serumfree Waymouth's medium containing 1.5 mg ml-' collagenase type IV (Sigma Chemical Co.) and 36 units of porcine pancreatic elastase (ICN, Costa Mesa, CA). Medium containing 10% serum (5 ml/sample) was added before mechanical dispersion. Our previous procedure was modified in that each sample was dispersed with two sequential 30 s bursts followed by two sequential 1 min bursts in a Stomacher blender (Techmar Co., Cincinnati, OH). Following each blender treatment, undispersed pieces were allowed to settle briefly, then each supernatant medium containing suspended cells was removed and replaced with DME-10. Pooled lung cell suspensions were centrifuged to pellet cells, resuspended in DME-10, and an aliquot was diluted with trypan blue to determine live and dead cells. No attempt was made to distinguish tumour cells from nucleated normal cells, but red blood cells were not counted. Cell suspensions consisted almost entirely of single cells.
Subcutaneous tumours were similarly removed and dispersed, using a different enzyme solution (Miller et al., 1990) , consisting of 10ml of DME-10 containing 2mgml1' collagenase type 3 (Worthington Biochemical Corp., Freehold, NJ) and 1 mg ml1' hyaluronidase (Sigma Chemical Co.), and similar Stomacher blender treatment. Cells from tumours were rinsed twice, then passed four times through a 25 g needle to achieve a single cell suspension (Miller et al., 1990 Dose-response curves All data in terms of colony forming cells per lung or tumour from each experiment were converted to a percentage of the mean control (vehicle-treated) value for that experiment. Regression analysis was used to fit the dose-response curve for each experiment. Values for ID90 were obtained from fitted curves. The shape of each dose response curve was also described by the parameters Do and Dq. Do was defined as the dose necessary to reduce colony formation by an amount l/e in the exponential portion of the curve. Thus it is proportional to the inverse slope. Dq, the quasi-threshold dose, was obtained by extrapolating the exponential portion of the curve upward until it crossed the horizontal line drawn through the control (100% survival) value. Thus it describes the width of the shoulder at low drug concentrations (Hall, 1988) . Throughout the dose range of Dq, the response per unit dose of drug is probably not zero, but it is clearly less than the final exponential rate of loss of colony forming ability seen at higher doses.
Results
Melphalan sensitivity in vitro We have previously described the sensitivity of lines 4T07 and 66 to 2 h treatment with melphalan in vitro (Miller et al., 1991) , by measuring the ability of each cell line to form colonies after treatment in monolayer culture. Figure 1 is the growth of line 4T07 in lungs of control and melphalantreated mice. The number of colony-forming cells increased exponentially in control mice over several days, with a doubling time of 13.7 h. Melphalan treatment had the effect of lowering the number of colony-forming cells per lung, as shown, but the doubling time of the surviving line 4T07 cells after treatment (13.4 h) was very similar to that in control mice. Comparison of the two lines at each time point suggests that the loss of colony-forming ability was slightly, but not significantly, higher when lungs were removed 1 h after treatment vs at later times. (The percent inhibition obtained by comparing the (geometric) mean number of colonyforming cells per lung in treated vs control animals was 91 % for lungs removed at 1 h, and 83% when all time points were pooled.) The similar loss of colony-forming ability when tumour cells were allowed to remain in situ several hours or days after treatment compared to those removed soon after treatments seems to indicate that repair of potentially lethal damage has very little effect in this system. In subsequent experiments, for convenience, mice were sacrificed and lungs removed either at 24 h after treatment, or at both 24 h and 48 h after treatment. Time after melphalan treatment (days) Figure 1 Growth in lungs of colony-forming cells of line 4T07 after melphalan treatment in vivo. Tumour cells (5 x 105/mouse) were injected i.v. Three days later, melphalan (12mgkg-') or vehicle was injected i.p. into 20 mice per treatment group. At various times (1 to 96h) after treatment, lungs from four mice per treatment group were removed, and cells were suspended and assayed for colony-forming ability in thioguanine medium. Points, means; bars, s.d.; solid line, regression line calculated using data from vehicle-treated mice; dashed line, regression line calculated using data from melphalan-treated mice.
between different treatment groups, between groups harvested at different times after cell injection, between groups injected with different numbers of tumour cells, nor between groups bearing line 4T07 vs line 66FAR tumour cells, indicating that the majority of total cells and live cells recovered were host cells rather than tumour cells. Differences in the number of cells able to form colonies in selective medium did exist between these groups, as indicated below. The number of colony-forming cells per lung was calculated for each mouse and plotted vs the melphalan dose. The data for one such experiment using line 4T07 are shown in Table II .The data for 12 such experiments in which animals bearing line 4T07 were treated with melphalan at various times after cell injection are shown in Figure 2 . In these experiments, we waited 24 h after treatment before removing lungs for assay. The data shown in Figure 2 are expressed as percent of clonogenic cells found in lungs of control (vehicle treated) mice. Only one-tenth as many tumour cells were injected into mice to be treated at day 9 and day 15, in order to insure that they would not have a huge tumour burden by the time of harvest. In addition, in one experiment of the five in which treatment was 3 days after cell injection (panel b), we injected 5 x I04 cells per mouse (see figure legend) .
Data for the 12 dose-response curves are summarised in Table III in terms of D., Dq, and ID90. Correlation coefficients obtained for the exponential portion of each curve described in Table II ranged from -0.6 to -0.9 using all data points, and -0.90 to -0.99 using mean values. There was little evidence of leveling off at higher dose levels. As shown in Table II Figure 2 and Table  III were carried out with line 66FAR. These experiments are shown in Figure 3 and Table IV. As shown in Table IV In Table VI , we have pooled one experiment done with line 66, the parent line of line 66FAR with two 66FAR experiments. Line 66 cannot be used in colony-forming assays using lung tissue because it does not have a selectable marker that allows it to be distinguished unambiguously from colonies formed from normal lung cells. However, very few normal cells isolated from subcutaneous tumours can form colonies under our assay conditions (B.E. Miller et al., 1987) , so this tumour cell line can be used in colony-forming assays from subcutaneous tumours. Treatment of line 66/ 66FAR in subcutaneous tumours yielded similar D. values to values obtained at day 3-14 in lungs. The Dq values for these experiments were also similar to those obtained at day 3-14 in lungs, and were thus significantly greater than Dg values obtained for line 4T07 in subcutaneous tumours (P< 0.05) . ID90 values for line 66/66FAR were also significantly greater than those obtained for line 4T07 (P< 0.05).
Thus, unlike the situation in early stages of metastasis, there appears to be a difference in sensitivity between line 4T07 and line 66/66FAR in late stage metastases and in subcutaneous tumours. This differences is confirmed by our previously published data indicating that subcutaneous tumours of line 66 are less sensitive to a single moderate dose of melphalan than are line 4T07 tumours (Miller et al., 1991) .
Discussion
We describe here a technique for measuring the drug sensitivity of tumour cells are various stages in the metastastic process, through the use of colony-forming assays to measure the proliferative capacity of tumour cells at various times after treatment. Such techniques are standard for measuring chemocytotoxicity in solid tumours; however, by use of tumour cells carrying drug-resistance markers and thus able to grow in selective medium, thereby preventing growth of the large excess of normal cells, we have been able to apply this technique to cells in occult metastases as well.
Data on the changes in sensitivity of tumour cells in lungs as a function of time after injection need to be seen in relation to the metastatic sequence. In order for tumour cells injected intravenously to form lung colonies, the cells must be arrested and retained in the lung, extravasate, and replicate in lung parenchyma. Previous studies with line 4T07 using similar colony-forming assays have shown that it arrests and grows in lung in a characteristic time-dependent manner which can be related to these several steps of metastasis (Aslakson et al., 1991a (Aslakson et al., , 1991b . The majority (>80%) of line 4T07 cells injected i.v. lodge very quickly in the lungs (Aslakson et al., 1991b) , but most of these cells are killed rapidly, so the number of tumour cells drops exponentially for approximately 8 h, with a half time for clearance of 2 to 4 h (Aslakson et al., 1991a (Aslakson et al., , 1991b . After 8 h the rate of tumour cell loss slows. As suggested by Liotta and DeLisi (1977) , this second phase correlates with the extravasation of line 4T07 cells from blood vessels into lung parenchyma (Aslakson et al., 1991b) . Since melphalan is a drug with a short half-life under physiological conditions (Parsons et al., 1981) , the contact of tumour cells with active drug must be of short duration and relatively soon after drug injection. At the time of earliest treatment, 45 min after injection, the tumour cells were nearly all arrested in the lung, but not extravasated. By the time of harvest 24 h after treatment, however, the surviving cells may have completed the extravasation process.
Sometime within 24 h after injection of line 4T07 cells, the number of colony-forming tumour cells starts to rise as cell replication begins to exceed cell death (Aslakson et al., 1991b) . The number of colony-forming line 4T07 cells increases exponentially between day 1 and at least day 7 after injection: previously measured doubling times in this growth period averaged 21 h (Aslakson et al., 1991a (Aslakson et al., , 1991b . Thus, when mice were treated with melphalan 3 days after cell injection, the cells were in a period of rapid exponential growth in the lungs.
Grossly visible nodules appear on the surface of lungs of untreated mice approximately 10 to 14 days after i.v. injection of line 4T07. When lungs of mice in experiments depicted in Figure 2 , panel d were examined prior to digestion, most lungs contained visible metastases. Although we have not measured the growth rate of colony-forming line 4T07 cells in mice with large tumour burdens in the lung, tumour cell growth rate is likely to slow as tumour nodules become larger. Thus, when mice were treated with melphalan 9 to 15 days after line 4T07 injection, the tumour cells were at this late stage of metastasis.
We have not analysed the time course of growth of untreated line 66FAR cells in the lung. However, studies similar to that described above for line 4T07 have been completed for the closely related line 66c14 (Aslakson et al., 1991a) . These studies show a pattern similar to that of line 4T07. Both line 66c14 and 66FAR grow more slowly in the lung that does line 4T07. The doubling time of line 66c14 averages 39h (Aslakson et al., 1991b) , whereas line 66FAR grows even more slowly (doubling time of 54 h, not shown). Nevertheless, visible metastatic nodules are found in the lung by day 13 to 20. Thus, when line 66FAR cells were treated with melphalan 3 or 8 days after cell injection, they were in a period of slow expansion of colony-forming cell number in the lungs. By day 14-19, metastatic deposits were large enough to be visible in many mice.
In solid tumours, it is a common observation that a treatment known to cause a relatively large tumour cell kill as determined by colony-forming assay may result in a relatively small effect on tumour growth or host survival time (Steel, 1977) . This may be due to a number of factors such as repair of potentially lethal damage in situ, rapid regrowth of tumour cells after treatment, and slow clearance of dead or damaged tumour cells in vivo. We have previously shown that melphalan treatment of subcutaneous tumours of line 4T07 results in an initial loss of colony-forming cells assayed 24 h after treatment, followed by a gradual increase in colonyforming cells per g tumour in treated mice so as to be indistinguishable from controls by day 14 after treatment (Miller et al., 1991) . We describe here that in lung metastases, the difference between the number of colony-forming tumour cells per lung in treated and untreated animals assayed within 1 h after treatment is only slightly more than differences seen on several days after melphalan treatment. This suggests that repair of potentially lethal damage in situ, which is likely to take place in the first days after treatment, is of small consequence in this system. However, the percent reduction in the number of metastatic nodules found at the time of necropsy was considerably smaller than the amount of tumour cell kill measured 24-48 h after treatment, indicating the somewhat transient effect of treatment. Although we saw no sign of accelerated regrowth of line 4T07 early after treatment (Figure 1) , it is likely that the tumour-burden in treated mice tends to 'catch up' to that in untreated mice as growth slows late in metastasis development. Increased survival time or cure in the ultimately desired effect of treatment, but it is important to determine immediate effects of treatment, even if they are transient, since such information may suggest the type and timing of subsequent effective treatment.
We have shown that tumour cell sensitivity to melphalan varies between cells at different stages in the metastatic process and between cell at early stages of metastasis vs cells in palpable subcutaneous tumours. In our experiments, cells treated relatively late in the metastatic process, after nodules had formed, responded very like cells in subcutaneous tumours. Such information obtained for a number of therapeutic agents may lead to combined therapy regimens tailored for specific disease stages. Some tumour cell lines appear to vary more than others in different stages of metastasis, so that two cell lines may be similar in sensitivity at one stage and differ at another. We have shown that line 66FAR and line 4T07 are very similar in sensitivity to melphalan when cells are treated very soon after i.v. injection and in early stages of growth in lungs, as well as being similarly sensitive in vitro. However, in late stages of growth in lungs and in subcutaneous tumours, line 4T07 is more sensitive to melphalan than is line 66FAR, becaue it has a more consistant loss of the low-dose shoulder of the dose-response curve. Indeed, line 4T07 cells in late metastases were actually more sensitive to low doses of drug than were 4T07 cells treated earlier, a result which, although counter-intuitive, is highly reproducible.
As we indicated previously, within the range obtained from replicate experiments, the size of the tumour burden did not systematically affect the dose-response curve parameters describing melphalan sensitivity in either cell line. On the other hand, there were large differences in mean tumour burden between experiments in which mice were treated and sacrificed early (day 0-1), at intermediate times (day 3-4) or late (day 14-15). These differences were particularly pronounced in line 4T07, which grew very rapidly in lungs, even though we injected 10 times as many cells into mice to be sacrificed early vs those to be sacrificed late, in order to partly compensate for these differences. (Steel, 1977) .
Melphalan is usually described as cell cycle independent; however, it has been shown to be somewhat more cytotoxic to cells in the M/Gl phase in at least one system (Bhuyan et al., 1972) . It is more cytotoxic for proliferating cells (Blosmanis et al., 1987) . It may be that cell cycle or cell proliferation differences between cells at various stages of metastasis are responsible for some of the differences in sensitivity to melphalan described here. However, the increased sensitivity to melphalan shown by line 4T07 in late stage metastasis and in palpable tumours is unlikely due to increased cell proliferation at these stages; in fact, relatively few line 4T07 cells are in cycle in subcutaneous tumours at any given moment (Miller et al., 1987) .
Some chemotherapeutic agents may be more or less effective in larger tumours because hypoxic conditions, increased cell contact, or other environmental effects may lead to mechanistically relevant changes in cellular metabolism. Changes in cellular metabolism which may occur at different stage of metastasis could affect sensitivity to melphalan.
Alternatively, cells at different metastatic stages may differ in sensitivity to melphalan because of differences in exposure to drug, or differences in ability to repair potentially lethal damage. It is possible that the increased sensitivity of both cell lines to melphalan when treated 45 min after cell injection may be due to increased drug exposure before cells have extravasated into lung parenchyma.
Studies with radiation have indicated that the extent of sublethal damage repair often correlates with the breadth of the shoulder in the acute dose-response curve (Hall, 1988) . In the case of melphalan cytotoxicity, Parsons reported that time-dependent repair of certain DNA-cross-links was correlated with resistance to melphalan cytotoxicity at low doses or short exposure times in one of two human melanoma lines (Parsons, 1984) . The fact that moderate to large shoulders were seen in dose response curves to melphalan from both of our cell lines at earlier stages of metastasis may suggest that both lines have the ability to repair sublethal damage under these growth conditions. However, with many chemotherapeutic agents, there is little correlation between the extent of the shoulder of a single dose-response curve and the appearance of sublethal damage repair determined by increased survival in split dose experiments (Hall, 1988) , sug-gesting that low dose shoulders reflect other metabolic effects affecting the threshold of drug toxicity such as reduced transport of drug at low concentrations. In the experiments described here, no shoulders or only small shoulders were seen in dose-response curves from four of four late-stage metastasis experiments with line 4T07, and from two of two subcutaneous tumour experiments with line 4T07, but from none of three subcutaneous tumour experiments and three latestage metastasis experiments with line 66FAR/66. It may be that slow-developing local microenvironmental effects or host reactions to tumour specific to line 4T07 may be instrumental in the loss of these low dose shoulders. Such loss has so far not been seen in a number of in vitro culture configurations, suggesting that factors unique to the in vivo environment may be involved. Two candidate microenvironmental factors are extent of vascularisation and extent of inflammatory cell infiltration, both of which vary between line 4T07 and line 66FAR/66 tumours. Experiments are in progress to test whether either of these factors contributes to the heightened melphalan sensitivity.
